Status:

COMPLETED

Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis

Lead Sponsor:

University of Alberta

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

PHASE2

Brief Summary

Manipulation of the intestinal microbiota through FMT is a potential therapeutic target for IBD patients. Studies are now required to determine if repeated FMT can overcome the apparent immune respons...

Detailed Description

same as above

Eligibility Criteria

Inclusion

  • Age \> 18 and \< 65 years
  • Diagnosis of UC for \> 3 months but \< 5 years prior to screening as determined by the investigators
  • Those with mild to moderate UC
  • Those who have failed maintenance therapy with stable doses of 5-ASA, azathioprine or 6 mercaptopurine (6-MP) for \> 3 months
  • Where applicable, those who are taking the following medications must be at a stable dose defined as:
  • i) 5-ASA must be at a stable dose for 2 weeks ii) Prednisone up to 20 mg/d must be at a stable dose for 2 weeks iii) Budesonide up to 6 mg/d must be at a stable dose for 2 weeks iv) Azathioprine or 6-MP must be at a stable dose for \> 8 weeks
  • ability to provide informed consent
  • evidence of active inflammation

Exclusion

  • Those whose disease is limited to the rectum (ie. proctitis)
  • Those with colectomy or diverting ileostomy
  • Those who are pregnancy or plan to be pregnant during the trial
  • Those who are breastfeeding or plan to breast feed during the trial
  • Those who are on or have previously failed a biological agent
  • Those with an active infection requiring antibiotic therapy
  • Those with positive stool cultures for known pathogens such as E coli, Salmonella, Shigella, Yersinia, Campylobacter, and Clostridium difficile toxin within 2 weeks of enrollment
  • Those with positive CMV on colonic tissue biopsy within 2 weeks of screening
  • Those with allergy to ciprofloxacin and metronidazole
  • Those with colonic mucosal dysplasia

Key Trial Info

Start Date :

July 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2016

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT02227342

Start Date

July 1 2014

End Date

December 1 2016

Last Update

December 14 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Alberta Hospital

Edmonton, Alberta, Canada